BlossomHill Therapeutics Announces Upcoming Presentation for BH-30236 at ASH
BlossomHill Therapeutics says BH-30236, an oral macrocyclic CLK inhibitor, will be presented at the 68th American Society of Hematology Annual Meeting.
Related stories
Dolphin to Host Q3 2026 Earnings Call on November 10
Dolphin said it will host its third-quarter 2026 earnings conference call on November 10, 2026.
M impact | EQUITY | Nov 04, 2026, 02:01 PM UTC
Immunome Reports 53% ORR in 19 B-NHL Patients
At the June 26, 2026 interim cutoff, 10 of 19 response-evaluable B-NHL patients had an overall response, including five complete and five partial responses. In the 11-patient DLBCL
M impact | EQUITY | Nov 04, 2026, 02:01 PM UTC
SM Energy Reports Third-Quarter Revenue of $2.17 Billion
Third-quarter net income was $93 million and diluted EPS was $0.39, compared with $155 million and $1.35 a year earlier. Production averaged 433.1 MBOE per day, down 2% sequentiall
M impact | EQUITY | Nov 04, 2026, 02:01 PM UTC
Nomad Foods Q3 Adjusted Earnings Fall as Revenue Rises
Nomad Foods maintained its 2026 adjusted earnings guidance.
M impact | EQUITY | Nov 04, 2026, 02:01 PM UTC
Scotiabank to announce fourth-quarter 2026 results
Scotiabank says it will announce its fourth-quarter results on Wednesday, Dec. The announcement date is incomplete in the source.
M impact | EQUITY | Nov 04, 2026, 02:00 PM UTC
Voyager Technologies Wins $35M NASA HUNCH Management Contract
Voyager Technologies was awarded a five-year contract to manage NASA’s HUNCH program, extending a role it has held since 2021.
M impact | EQUITY | Nov 04, 2026, 02:00 PM UTC